Bal Pharma is currently trading at Rs. 82.05, up by 2.35 points or 2.95% from its previous closing of Rs. 79.70 on the BSE.
The scrip opened at Rs. 79.65 and has touched a high and low of Rs. 84.30 and Rs. 79.50 respectively. So far 1873 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 128.00 on 01-Jan-2018 and a 52 week low of Rs. 69.55 on 25-May-2018.
Last one week high and low of the scrip stood at Rs. 84.30 and Rs. 76.50 respectively. The current market cap of the company is Rs. 113.17 crore.
The promoters holding in the company stood at 42.45%, while Institutions and Non-Institutions held 0.20% and 57.34% respectively.
Bal Pharma has commenced commercial production of intermediates and Active Pharma Ingredients (API) at its bulk drugs manufacturing unit in Udaipur. The APL products which of scheduled to be manufactured at this Unit were developed by the company’s R&D facility at Bangalore and due to capacity constraints at Bangalore facility it could not become commercially viable till now.
This unit is expected to ease the capacity concerns of API's and intermediates and will cater to the North are Northeastern markets of the country and also overseas markets.
Bal Pharma is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1831.45 |
Dr. Reddys Lab | 1190.95 |
Cipla | 1562.50 |
Lupin | 2114.50 |
Zydus Lifesciences | 898.05 |
View more.. |